HIV-1/-2 Antibody Evaluation, Serum
Method Description Describes how the test is performed and provides a method-specific reference
The VITROS Anti-HIV 1+2 assay is performed using the VITROS Immunodiagnostic Products Anti-HIV 1+2 Reagent Pack and the VITROS Immunodiagnostic Products Anti-HIV 1+2 Calibrator. An immunometric bridging technique is used, involving a 2-stage reaction. In the first stage, HIV antibody present in the sample binds with HIV recombinant antigen coated on the wells. Unbound sample is removed by washing. In the second stage, horseradish peroxidase (HRP)-labeled recombinant HIV antigens are added in the conjugate reagent. The conjugate binds specifically to any human anti-HIV-1 or anti-HIV-2 (IgG and IgM) captured on the well in the first stage. Unbound conjugate is removed by washing. The bound HRP conjugate is measured by a luminescent reaction. A reagent containing luminogenic substrates (a luminol derivative and a peracid salt) and an electron transfer agent is added to the wells. The HRP in the bound conjugate catalyzes the oxidation of the luminol derivative, producing light. The electron transfer agent (a substituted acetanilide) increases the level of light produced and prolongs its emission. The light signals are read by the VITROS ECi/ECiQ Immunodiagnostic System. The amount of HRP conjugate bound is indicative of the level of anti-HIV-1 or anti-HIV-2 present.(Package insert: VITROS Anti-HIV 1+2, Ortho Clinical Diagnostics Inc., Raritan, NJ; publication no. GEM1252_EN)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Saturday; Varies